Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.

Cancer biology & therapy - 1 Dec 2013

Esposito Claudia, Rachiglio Anna Maria, La Porta Maria Libera, Sacco Alessandra, Roma Cristin, Iannaccone Alessia, Tatangelo Fabiana, Forgione Laura, Pasquale Raffaella, Barbaro Americo, Botti Gerardo, Ciardiello Fortunato, Normanno Nicola

Abstract excerpt

The activity of the epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab in metastatic colorectal carcinoma (mCRC) is significantly limited by molecular mechanisms leading to intrinsic or acquired resistance. The S492R mutation of the EGFR, which is caused by either the 1476C>A or the 1474A>C substitution, interferes with binding to cetuximab but not to panitumumab, and has been detected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to ErbB Receptors

Share to Panitumumab

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24025416
DOI: 10.4161/cbt.26340
PMCID: PMC3912037

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.PMID 24025416Read ↗

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.Semantic proximity Read ↗

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patientsSemantic proximity Read ↗

Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.Semantic proximity Read ↗

First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.Semantic proximity Read ↗

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.Semantic proximity Read ↗

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.Semantic proximity Read ↗

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.Semantic proximity Read ↗

RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine.Semantic proximity Read ↗

EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.Semantic proximity Read ↗

HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy.Semantic proximity Read ↗

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.